Chiome Bioscience Inc. (TYO:4583)
75.00
-2.00 (-2.60%)
Jul 16, 2026, 9:59 AM JST
Chiome Bioscience Revenue
Chiome Bioscience had revenue of 147.16M JPY in the quarter ending March 31, 2026, with 6.10% growth. This brings the company's revenue in the last twelve months to 601.75M, down -23.82% year-over-year. In the year 2025, Chiome Bioscience had annual revenue of 593.29M, down -24.02%.
Revenue (ttm)
601.75M
Revenue Growth
-23.82%
P/S Ratio
9.79
Revenue / Employee
11.35M
Employees
53
Market Cap
5.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 593.29M | -187.52M | -24.02% |
| Dec 31, 2024 | 780.81M | 98.35M | 14.41% |
| Dec 31, 2023 | 682.46M | 51.65M | 8.19% |
| Dec 31, 2022 | 630.82M | -82.12M | -11.52% |
| Dec 31, 2021 | 712.93M | 232.08M | 48.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kohjin Bio | 4.94B |
| Soiken Holdings | 4.40B |
| CellSource | 3.67B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 711.65M |
| Carna Biosciences | 619.35M |
| D. Western Therapeutics Institute | 305.97M |
| ADR Biomedical Holdings | 50.00M |